{
    "id": 8747,
    "name": "subacute myeloid leukemia",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "8746",
        "8993"
    ],
    "termId": "DOID:8747",
    "evidence": [
        {
            "id": 8245,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Cytosar-U (cytarabine) combination treatment synergistically induced cell death in patient-derived acute myeloid leukemia cells in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3182,
                "therapyName": "Cytarabine + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8747,
                "name": "subacute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10952,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG-564 induced cytotoxicity of CD33-positive acute myeloid leukemia (AML) cells in culture, and inhibited tumor growth in a CD33-positive AML cell line xenograft model (PMID: 27189165).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 5711,
                "therapyName": "AMV-564",
                "synonyms": null
            },
            "indication": {
                "id": 8747,
                "name": "subacute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8953,
                    "pubMedId": 27189165,
                    "title": "Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27189165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01305499",
            "title": "A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2645,
                    "therapyName": "Azacitidine + Entinostat",
                    "synonyms": null
                }
            ]
        }
    ]
}